PetVivo Holdings Inc (PETV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PetVivo Holdings Inc (PETV) has a cash flow conversion efficiency ratio of -0.438x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.63 Million) by net assets ($3.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PetVivo Holdings Inc stock valuation for the company's overall valuation and market capitalisation.
PetVivo Holdings Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how PetVivo Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PetVivo Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PetVivo Holdings Inc ranked by their cash flow conversion efficiency. Explore PETV operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GFM Services Bhd
KLSE:0039
|
0.040x |
|
K Way Information
TWO:5201
|
-0.031x |
|
Dongwoo Farm To Table Co.Ltd
KQ:088910
|
0.003x |
|
DCM Nouvelle Limited
NSE:DCMNVL
|
0.537x |
|
Wisr Ltd
AU:WZR
|
0.105x |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
-0.182x |
|
Ecoplastic Corporation
KQ:038110
|
0.021x |
|
Haverty Furniture Companies Inc
NYSE:HVT-A
|
0.104x |
Annual Cash Flow Conversion Efficiency for PetVivo Holdings Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of PetVivo Holdings Inc from 2011 to 2025. View PETV stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $4.22 Million | $-5.32 Million | -1.261x | +88.34% |
| 2024-03-31 | $685.95K | $-7.42 Million | -10.816x | -15.42% |
| 2023-03-31 | $725.02K | $-6.79 Million | -9.371x | -1243.82% |
| 2022-03-31 | $5.99 Million | $-4.17 Million | -0.697x | -159.73% |
| 2021-03-31 | $-896.98K | $-1.05 Million | 1.168x | +143.63% |
| 2020-03-31 | $-1.04 Million | $-496.59K | 0.479x | -45.02% |
| 2019-03-31 | $-844.82K | $-736.45K | 0.872x | +120.57% |
| 2018-03-31 | $136.65K | $-579.15K | -4.238x | -2329.30% |
| 2017-03-31 | $819.75K | $-143.02K | -0.174x | -284.41% |
| 2016-03-31 | $15.21 Million | $-690.33K | -0.045x | +98.16% |
| 2015-03-31 | $161.25K | $-398.48K | -2.471x | -440.34% |
| 2014-03-31 | $-301.81K | $-219.13K | 0.726x | +90.00% |
| 2013-03-31 | $-184.51K | $-70.51K | 0.382x | +37.56% |
| 2012-03-31 | $-177.62K | $-49.34K | 0.278x | -87.92% |
| 2011-03-31 | $-74.99K | $-172.42K | 2.299x | -- |
About PetVivo Holdings Inc
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for … Read more